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Amphiregulin Carboxy-Terminal Domain Is Required
for Autocrine Keratinocyte Growth
Stefan W. Stoll1, Jessica L. Johnson1, Yong Li1, Laure Rittie´1 and James T. Elder1,2
The EGFR ligand amphiregulin (AREG) has been implicated as an important autocrine growth factor in several
epithelial malignancies and in psoriasis, a hyperproliferative skin disorder. To characterize the mechanisms by
which AREG regulates autocrine epithelial cell growth, we transduced human keratinocytes (KCs) with lentiviral
constructs expressing tetracycline (TET)-inducible small hairpin RNA (shRNA). TET-induced expression of AREG
shRNA markedly reduced autocrine extracellular signal-regulated kinase phosphorylation, strongly inhibited
autocrine KC growth with an efficiency similar to metalloproteinase and EGFR inhibitors, and induced several
markers of KC differentiation, including keratins 1 and 10. Addition of various concentrations of exogenous
EGFR ligands to KC cultures reversed the growth inhibition in response to AREG-blocking antibodies but not to
shRNA-mediated AREG knockdown. Lentivirus-mediated expression of the full-length AREG transmembrane
(TM) precursor, but not of the AREG extracellular domain, markedly reversed the shRNA-mediated growth
inhibition and morphological changes, and strongly reduced the induction of multiple markers of KC
differentiation. Taken together, our data show that autocrine human KC growth is highly dependent on the
AREG TM precursor protein and strongly suggest a previously unreported function of the metalloproteinase-
processed carboxy (C)-terminal domain of AREG.
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INTRODUCTION
The EGFR is the prototypical member of the c-ErbB family of
transmembrane (TM) receptor tyrosine kinases, which also
includes ErbB2, ErbB3, and ErbB4 (Olayioye et al., 2000).
Binding of EGFR ligands and neuregulins to ErbB receptors
results in receptor dimerization and activation of signaling
pathways that regulate a multitude of cellular responses
(Iordanov et al., 2002; Kansra et al., 2004). EGFR, ErbB2, and
ErbB3 are expressed in normal human keratinocytes (NHKs)
and skin (Marques et al., 1999; De Potter et al., 2001; Stoll
et al., 2001) and EGFR-mediated signaling regulates
keratinocyte (KC) migration, proliferation, and differentiation
(Pittelkow et al., 1993; Peus et al., 1997; Tokumaru et al.,
2000; Piepkorn et al., 2003; Ferby et al., 2006).
The mammalian EGFR ligand family comprises seven
members (Sanderson et al., 2006; Pastore et al., 2008),
several of which are expressed in KCs, including amphir-
egulin (AREG; Cook et al., 1991), epigen (EPGN; Strachan
et al., 2001; Stoll et al., 2010), epiregulin (Shirakata et al.,
2000), heparin-binding EGF-like growth factor (HB-EGF;
Hashimoto et al., 1994), and transforming growth factor-a
(TGF-a; Coffey et al., 1987). EGFR ligands are synthesized as
TM precursors with an N-terminal extracellular region that
contains the EGF domain characterized by a motif of six
spatially conserved cysteine residues (Sanderson et al., 2006).
Mature forms of EGFR ligands are released into the
extracellular milieu from their membrane-bound precursors
via metalloproteinase (MP)-mediated proteolytic cleavage,
and various members of the ADAM family, including
ADAM10 and 17, have been implicated in this process
(Peschon et al., 1998; Sunnarborg et al., 2002; Yan et al.,
2002; Hinkle et al., 2004; Sahin et al., 2004). However, the
exact identities of the MP(s) required for EGFR ligand
shedding in KCs are still under investigation.
The expression of at least five EGFR ligands by human KCs
raises the question why the KC EGFR system relies on
multiple ligands. Findings from multiple laboratories includ-
ing ours suggest the existence of non-redundant, EGFR-
dependent signaling mechanisms that are activated in
different cellular contexts. For example, we and others have
previously shown that HB-EGF is important for KC migration
(Tokumaru et al., 2000; Stoll et al., 2010). In contrast,
autocrine KC proliferation and extracellular signal-regulated
kinase (ERK) phosphorylation are selectively inhibited by
neutralizing antibodies (Abs) against AREG (Kansra et al.,
2004; Bhagavathula et al., 2005; Stoll et al., 2010).
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AREG is synthesized as a 252 amino-acid-precursor
protein, which undergoes post-translational modifications
via N-linked glycosylation and proteolytic processing result-
ing in multiple membrane-bound (16, 26, 28 and 50 kDa) and
soluble isoforms (9, 19, 21 and 43 kDa; Brown et al., 1998).
Its name reflects the finding that it can either stimulate or
inhibit the growth of various normal and cancer cell lines
(Shoyab et al., 1988). AREG has been implicated in
pathologies of various organs including the breast, colon,
liver, and prostate (Katoh and Katoh, 2006). In the skin,
AREG, HB-EGF, and TGF-a are overexpressed in the
hyperproliferative epidermis of psoriatic lesions (Elder et al.,
1989; Cook et al., 1992; Stoll and Elder, 1998) and transgenic
mice overexpressing AREG develop a psoriasiform derma-
tosis with many similarities to psoriasis (Cook et al., 1997,
2004). In contrast, mice with transgenic expression of TGF-a
or HB-EGF display only limited epidermal hyperplasia with
little cutaneous inflammation (Vassar and Fuchs, 1991;
Dominey et al., 1993).
The objective of this study was to explore the mechanisms
by which AREG promotes autocrine KC proliferation. To this
end, we asked whether AREG gene silencing would block KC
growth in a manner that could be reversed by treatment of
KCs with exogenous growth factors. A more general objective
of this study was to establish an experimental system that
allows conditional knockdown of the expression of any gene
in human KCs.
RESULTS
To address the importance of AREG in KC physiology, we
established an experimental system that allows lentivirus-
mediated conditional knockdown of gene expression in
human KCs. Immortalized but non-transformed N-TERT-2G
KCs (Dickson et al., 2000) previously infected with a
lentiviral construct encoding tetracycline repressor (TR)
protein (Stoll et al., 2010) were stably transduced with small
hairpin RNAs (shRNAs) against AREG or enhanced green
fluorescent protein (EGFP) under the control of a tetracycline
(TET)-regulated histone H1 promoter, or transduced with a
lentivirus construct encoding EGFP under the control of a
TET-regulated cytomegalovirus promoter. After stable selec-
tion with antibiotics, these cell lines were termed N-TERT-TR-
shAREG (AREG shRNA), N-TERT-TR-shEGFP (EGFP shRNA),
and N-TERT-TR-EGFP (EGFP complementary DNA).
First, we tested the regulation of the TET-inducible system
using N-TERT-TR-EGFP cells. Addition of TET leads to
conformational changes of the TR protein, which prevents
its binding to the TET operator sequences in the cytomega-
lovirus or H1 promoter, thereby resulting in the induction of
gene or shRNA expression. As demonstrated by western
blotting and immunofluorescence in Figure 1a, EGFP
expression was strongly repressed by the TET repressor
protein in untreated cells, but was rapidly induced upon
addition of TET.
We next examined the effect of TET treatment on AREG
gene expression in the N-TERT-TR-shAREG cells by quanti-
tative real-time PCR. As can be seen in Figure 1b, TET-
induced expression of AREG shRNA but not EGFP shRNA for
24 and 48 hours significantly inhibited AREG mRNA levels by
more than 83%.
To control for non-specific shRNA effects we also
measured the expression of interferon-g stress-response
genes, including protein kinase and 20,50-oligoadenylate
synthetase (Hovanessian, 2007), in N-TERT-TR-shAREG cells.
TET-induced expression of AREG shRNA did not significantly
change the transcript levels of these genes (data not shown).
Using AREG-specific ELISAs, we tested the effects of
shRNA expression on cell-associated AREG protein levels in
N-TERT-TR-shAREG and N-TERT-TR-shEGFP cells. In the
absence of TET, both cell lines displayed a similar pattern of
AREG protein expression, with AREG levels ranging between
3 and 12 ng per mg of total protein lysate at the various time
points tested (data not shown). TET-induced expression of
AREG shRNA reduced cell-associated AREG protein levels by
more than 71% at all time points (Po0.02). In contrast, no
significant reduction of AREG protein levels was observed in
response to EGFP shRNA expression (Figure 1c). Expression
of AREG shRNA but not EGFP shRNA also significantly
(Po0.001) reduced shed AREG in KC supernatants by more
than 95% at all time points (Figure 1d).
As depicted in Figure 2a, AREG was the most prominent
EGFR ligand in both NHKs and N-TERT KCs with all other
EGF family ligands being expressed at significantly lower
levels. AREG mRNA expression was found to be highly
similar whether TaqMan assays specific for the intracellular
domain (AREG #1) or the extracellular domain (ECD; AREG
#2 and 3) were used. Soluble AREG in the culture medium
was also very similar in NHKs and N-TERT KCs (Figure 2b).
Using blocking Abs, we have earlier shown that autocrine
ERK phosphorylation and proliferation of NHKs are mediated
by shed AREG (Stoll et al., 2010). To confirm these data, we
tested the effects of conditional knockdown of AREG on ERK
phosphorylation in KCs incubated in a growth factor-free
culture medium. As previously described, using anti-AREG
Abs in NHKs (Kansra et al., 2004) autocrine ERK phosphory-
lation was markedly inhibited in N-TERT KCs by AREG-
neutralizing Abs and AREG shRNA, but not by EGFP shRNAs
(Figure 3a). Similar to NHKs (Stoll et al., 2010), autocrine
ERK phosphorylation in N-TERT KCs was also strongly
reduced in response to the MP inhibitor GM6001 and the
ErbB tyrosine kinase inhibitor PD158780 (Figure 3a).
Notably, TET treatment did not alter EGF-induced ERK
phosphorylation (Figure 3b).
We next examined the effects of AREG knockdown on
autocrine KC growth by performing growth assays in the
presence or absence of TET, with and without EGFR and MP
inhibitors and/or EGFR ligand-blocking Abs. A picture of a
typical result is shown in Figure 4a and quantifications of
multiple experiments are shown in Figure 4b. TET-driven
conditional knockdown of AREG reduced KC growth by
more than 86% relative to untreated controls. In contrast, TET
treatment of N-TERT-TR-shEGFP (Figure 4a and b) or N-TERT-
TR cells (data not shown) did not inhibit KC growth. Growth
of N-TERT KCs was also strongly inhibited by the ErbB
tyrosine kinase inhibitor PD158780, the anti-EGFR Ab
IgG225, and the MP inhibitor GM6001. Surprisingly, and in
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stark contrast to their effects on autocrine ERK phos-
phorylation, inhibition of N-TERT growth by shRNA was
significantly greater than that by anti-AREG (Po0.05). Similar
to NHKs (Stoll et al., 2010), growth of N-TERT-TR-shAREG
cells in the absence of TET was not reduced in response to
neutralizing Abs against HB-EGF (Figure 4a and b) or TGF-a
(Figure 4a).
Induction of AREG shRNA but not EGFP shRNA markedly
changed the KC morphology, with the appearance of tightly
packed colonies made of many small and refractile
cells (Figure 4c). Quantitative real-time PCR analysis of
RNA from AREG knockdown cells revealed a strong
induction (4100-fold) of several markers of KC differentia-
tion, including keratin 1 and 10, involucrin, and loricrin, and
to a lesser extent transglutaminase 1 (48-fold increase,
Figure 4d). In contrast, induction of EGFP shRNA resulted in
only minor changes in the expression of these differentiation
markers (Figure 4d).
To explore the mechanisms of differential inhibition of KC
growth by AREG knockdown versus AREG neutralizing Abs,
we asked whether exogenous EGF-like growth factors could
rescue the effects of AREG knockdown. To this end, we
incubated N-TERT-TR-shAREG KCs in the presence or
absence of TET- or AREG-neutralizing Abs, with and without
various concentrations of recombinant EGFR ligands. Addi-
tion of EGF or AREG to N-TERT-TR-shAREG cells in the
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Figure 1. Amphiregulin (AREG) expression is strongly inhibited by tetracycline (TET)-induced expression of AREG small hairpin RNA (shRNA). (a) Inducible,
lentivirus-mediated gene expression is tightly regulated by TET as assessed by enhanced green fluorescent protein (EGFP) immunofluorescence and
immunoblotting. The photographs in the upper panel were taken with identical exposure times. Bar¼ 200mm. The ‘‘þ ’’ and ‘‘’’ labels on the immunoblot
indicate±TET. (b) AREG mRNA expression. N-TERT-keratinocytes (KCs) were grown under autocrine conditions±TET and analyzed by quantitative real-time
PCR. Asterisks denote a significant reduction in gene expression relative to untreated controls, Po0.005, n¼2 for shEGFP, n¼ 5 for shAREG. (c, d) AREG
protein expression. N-TERT KCs were grown under autocrine conditions ±TET for 48 hours (48 hours pre-TX), followed by incubation for an additional
2–24 hours in basal keratinocyte serum-free medium (KSFM)±TET. AREG protein levels were analyzed in radioimmunoprecipitation assay extracts (c) or in KC-
conditioned medium (d) by ELISA as described in Materials and Methods. Data are expressed as % of controls, *Po0.02 (c) or Po0.001 (d) versus untreated
controls (n¼ 4 for all conditions, except n¼ 2 for shEGFP at 2 and 14 hours).
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absence of TET did not markedly alter autocrine KC growth
(Supplementary Figure S1 online). Surprisingly, recombinant
EGF, HB-EGF, EPGN, and/or TGF-a or even 100ng per ml of
AREG could not compensate for the growth inhibition caused
by knockdown of endogenously expressed AREG (Figure 5a).
In stark contrast, inhibition of KC growth by anti-AREG Abs
could be reversed by EGFR ligands. As can be seen in Figure
5b, maximum inhibition of N-TERT growth was reached with
5 mg per ml of AREG Abs. Addition of EGF to cultures treated
with saturating amounts of anti-AREG Abs restored cell
growth to levels similar to those in untreated controls and
prevented the appearance of differentiated cells that were
observed in cultures incubated with Abs alone (Figure 5c).
Notably, EGFR ligand treatment markedly changed the KC
morphology in AREG knockdown cells, with the appearance
of large, flattened, and multinucleated cells (Figure 5c).
The marked differences between the effects of AREG-
blocking Abs and AREG shRNA prompted us to address the
importance of the cell-associated domain of AREG in
regulating KC growth and differentiation. To explore this,
we stably transduced N-TERT-TR-shAREG cells with a
constitutive lentiviral expression vector encoding comple-
mentary DNA for the AREG ECD or the full-length AREG TM
precursor. An overview depicting the constructs used, the
targeting shRNA, and the approximate location of the
TaqMan gene-expression assays is provided in Figure 6a.
These constructs were effectively transcribed in the newly
generated cell lines (N-TERT-TR-shAREG/ECD and N-TERT-
TR-shAREG/TM) in the absence of TET, and were not targeted
by the 30-untranslated region-specific shRNA (þ TET; Figure
6b). This figure also demonstrates the detection of AREG
expression of both constructs with a TaqMan assay specific
for the ECD (Hs00950669), whereas assay Hs00155832 only
detects the TM precursor.
Using these constructs, we next examined the effects of
AREG topology on autocrine KC growth. Both cell lines grew
equally well in the absence of TET (Figure 6c); however, after
TET-induced AREG knockdown, the AREG-TM precursor
restored KC growth whereas the AREG ECD was ineffective.
As previously shown in Figure 5b, recombinant EGF
(20 ngml1) or AREG (100 ngml1) did not improve
shAREG-mediated inhibition of KC growth.
Similar to its effects on N-TERT KC growth, lentivirus-
mediated expression of the full-length AREG TM precursor
(but not the AREG ECD) rescued normal cell morphology and
strongly prevented the formation of small cell colonies with
differentiated cells in the presence of TET (Figure 6d).
Consistent with its effects on growth and cell morphology,
quantitative real-time PCR analysis indicated that the TM
precursor of AREG prevented the TET-induced expression of
markers of KC differentiation, including keratins 1 and 10, to
a much greater extent than the ECD of AREG alone
NHK N-TERT
AR
EG
 #1
AR
EG
 #2
AR
EG
 #3 BT
C
EG
F
EP
GN
ER
EG
HB
-EG
F
TG
F-α
*
80
70
60
50
40
30
20
10
0
NHK N-TERT
6
5
4
3
2
1
0
AR
EG
 p
ro
te
in
, n
g 
m
l–1
m
R
N
A 
le
ve
ls,
 
%
 o
f 3
6B
4
Figure 2. Epidermal growth factor receptor (EGFR) ligand expression and
shedding in normal human keratinocytes (NHKs) and N-TERT keratinocytes
(KCs). KCs were grown to 40% confluence and incubated in basal medium for
24 hours. Culture supernatants were collected for ELISA and the cells were
lysed for quantitative real-time PCR analysis. (a) Relative EGFR-ligand
transcript levels were analyzed by quantitative real-time PCR using TaqMan
gene-expression assays (Applied Biosystems, Foster City, CA) as previously
described (Stoll et al., 2010). Amphiregulin (AREG) mRNA expression was
analyzed with three different TaqMan assays (Applied Biosystems; assay #1:
HS00155832; assay #2: HS00950668; assay #3: HS00950669). Data are
expressed as % of 36B4 transcript levels, mean±SEM, n¼ 3, *Po0.05 versus
all other EGFR ligands. (b) KC supernatants conditioned for 24 hours were
analyzed by ELISA for the presence of shed AREG. Data are expressed as ng
of soluble AREG per ml of supernatant.
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Figure 3. Autocrine extracellular signal regulated kinase (ERK)
phosphorylation is reduced in the presence of amphiregulin (AREG) small
hairpin RNA (shRNA). N-TERT-tetracycline repressor (TR) shAREG or shEGFP
was grown under autocrine conditions for 48 hours as described in Materials
and Methods, followed by treatments as described below, and
radioimmunoprecipitation assay lysates were analyzed by ERK and phospho-
ERK western blotting. (a) Cells were incubated in fresh M154 medium for
2–4 hours ±TET, with or without 5 mgml1 AREG-neutralizing antibodies
(Abs) or IgG isotype control or 1 mM PD158780, 40 mM GM6001, or
100 ngml1 epidermal growth factor (EGF). (b) Cells were incubated in fresh
M154 medium ±TET for 30minutes, followed by treatment with EGF
(20 ngml1) or AREG (100 ngml1) for 10minutes.
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(Figure 6e). Given that KC differentiation in cultures is
associated with reduced expression of EGFR (Boonstra et al.,
1985), we also asked whether TET-induced expression of AREG
shRNA influences EGFR mRNA levels. As expected, EGFR
expression was significantly reduced by AREG shRNA (Supple-
mentary Figure S2 online). Consistent with the partial reversion
of the differentiated phenotype by the AREG-TM precursor,
EGFR expression remained low even in the presence of the non-
targeted AREG constructs (Supplementary Figure S2 online).
DISCUSSION
Autocrine EGFR activation by multiple ligands has been well
described in proliferating KCs in vitro (Coffey et al., 1987;
Barnard et al., 1994; Hashimoto et al., 1994; Piepkorn et al.,
1994; Shirakata et al., 2000), but it has remained unclear why
the EGFR signaling network relies on more than one ligand.
We have previously shown that distinct EGFR ligands
stimulate KC behavior in different cellular contexts, HB-EGF
favoring a pro-migratory phenotype of skin KCs as opposed to
the autocrine-proliferative effect of AREG ligands (Kansra
et al., 2004; Stoll et al., 2010). To further delineate the
mechanism by which AREG stimulates autocrine KC growth,
we established an in vitro system that allows conditional
knockdown of gene expression in human KCs. Using a TET-
inducible EGFP expression construct, we show that this system
is tightly regulated, and that TET-induced expression of AREG,
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Figure 4. Amphiregulin (AREG) knockdown strongly inhibits autocrine keratinocyte (KC) growth and promotes KC differentiation. Cell growth assays were
performed on N-TERT-tetracycline repressor (TR)-shAREG or N-TERT-TR-shEGFP ±tetracycline (TET), with and without PD158780 (1mM), GM6001 (40mM), or
neutralizing antibodies (Abs) against EGFR or its ligands (each at 5mgml1). (a) Cells were stained with crystal violet and photographed. Each photograph represents
duplicate wells. (b) KC growth was evaluated by hemocytometer counting. Data are expressed as cell number, % of untreated controls; mean±SEM, n¼2–7, *Po0.05,
**Po0.005 versus untreated controls. (c) Morphology of N-TERT-KCs at the end of growth assays. Bar¼ 200mm. (d) Quantitative real-time PCR of various markers of
KC differentiation. Data are expressed as % of 36B4 (mean±SEM, n¼ 6, *Po0.05, **Po0.005, ***Po0.0001 versus () TET controls, NS¼not significant).
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but not EGFP shRNAs, strongly reduces AREG mRNA and
protein expression in N-TERT KCs (Figure 1). The proteolytic
release of soluble EGFR ligands from their membrane-bound
precursors is important for their proper function (Sanderson
et al., 2006). Our data also show that TET-induced expression
of AREG shRNA strongly reduces the presence of soluble
AREG in KC supernatants by more than 90%. The use of
1mgml1 TET in our experiments had no inhibitory effect on
AREG shedding as shown in our control cells (Figure 1d,
N-TERT-TR-shEGFP). Together, the results in Figure 1 strongly
validate the TET-inducible lentivirus system as a powerful tool
to study gene function in human KCs.
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Figure 5. Inhibition of autocrine keratinocyte (KC) growth by amphiregulin (AREG) small hairpin RNA (shRNA) cannot be reversed by addition of
recombinant EGFR ligands. Cell growth assays were performed using N-TERT-tetracycline repressor (TR)-shAREG cells in the presence or absence of EGFR
ligands ± tetracycline (TET) or ±AREG-blocking antibodies (Abs). Cell counts were determined in the presence or absence of TET (a) or AREG blocking Abs
(b). Data are expressed as total cell number. Error bars indicate SEM, n¼3–8 except epigen (EPGN), n¼2. All TET-treated conditions in Figure 5a were
significantly reduced (Po0.05) versus () TET controls. Asterisks in b indicate significant changes versus controls without anti-AREG or EGF (Po0.05).
(c) KC cell morphology at the end of the growth assay. Arrows indicate groups of differentiated cells that were observed in cultures incubated with anti-AREG
or TET. Bar¼ 200mm.
Figure 6. Amphiregulin (AREG) transmembrane (TM) precursor restores keratinocyte (KC) proliferation and prevents KC differentiation in AREG
knockdowns. N-TERT-tetracycline repressor (TR)-shAREG were infected with lentivirus constructs encoding the AREG extracellular domain (ECD) or complete
AREG (TM) precursor. After selection, cells were used in cell-growth assays. (a) Overview of the protein domain structure of the AREG TM precursor, soluble
mature AREG, and AREG expression constructs. The approximate location of the TaqMan gene expression assays (Applied Biosystems) is indicated.
The small hairpin RNA (shRNA) targets a sequence in the 30 untranslated region of the AREG mRNA (nucleotide position 998–1,019 of Genbank # M30704).
(b) AREG expression in N-TERT using expression assays specific either for the TM or for both constructs as shown in a (mean±SEM, n¼ 4–7, #Po0.005 versus
() tetracycline (TET) controls, *Po0.05 and **Po0.005 versus N-TERT-TR-shAREG with and without TET, respectively). (c) Crystal violet staining of growth
assays with N-TERT-TR-shEGFP and N-TERT-TR-shAREG cell lines incubated in the presence or absence of TET±epidermal growth factor (EGF) or AREG.
(d) KC morphology at the end of the growth assays. Bar¼ 200mm. (e) quantitative real-time PCR analysis of markers of KC differentiation. The data for N-TERT-
TR-shAREG are the same as in Figure 4d and are included here for comparison. Error bars indicate mean±SEM, n¼ 4–7, *Po0.05, **Po0.005 versus
TET-treated N-TERT-TR-shAREG.
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In our investigation, we used immortalized but non-
transformed N-TERT-2G KCs (Dickson et al., 2000), which
allowed us to select stable cell lines, thereby minimizing
the experimental variability of transient infections, while the
TET-inducible system allowed us to surmount the growth-
inhibitory effects of AREG knockdown. We also show that
AREG is the most abundantly expressed EGFR ligand in
N-TERT KCs and that NHKs and N-TERT KCs show very
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similar levels of AREG shedding (Figure 2), which supports the
use of immortalized N-TERT cells for the study of KC function.
Using the conditional shRNA expression system, we
confirm our earlier data with blocking Abs that AREG
controls the self-sustained proliferation and ERK phosphor-
ylation of NHKs (Stoll et al., 2010). We show that ERK
phosphorylation is markedly reduced in response to AREG
knockdown (Figure 3) and that AREG shRNAs strongly inhibit
KC proliferation and promote KC differentiation (Figures 4
and 5). Interestingly, ERK phosphorylation was more
effectively blocked by anti-AREG Abs, whereas AREG
shRNAs were much more inhibitory to KC growth (Figures
3–5). Furthermore, EGFR ligand treatment reversed the
shRNA-induced effect on ERK phosphorylation (Figure 3),
but not the shRNA-mediated growth inhibition (Figure 5).
These findings suggest that ERK phosphorylation by itself is
not sufficient to sustain KC growth even though ERK activity is
required for KC proliferation (Kim et al., 2008). Our data
suggest an important function for KC-derived full-length
AREG in this process.
It is still unclear why KC proliferation depends so strongly
on AREG function. One obvious explanation is that KCs
express far more AREG than any other EGF-like growth factor
(Stoll et al. (2010) and Figure 2). However, this phenomenon
could also involve altered trafficking of receptor–ligand
complexes. AREG and EPGN were earlier shown to have
superior mitogenic activity compared with EGF or TGF-a,
even though they are low-affinity EGFR ligands (Adam et al.,
1995; Kochupurakkal et al., 2005). It was suggested that their
high mitogenic potential might be due to evasion of receptor-
mediated endocytosis, which targets receptor–ligand com-
plexes for intracellular degradation (Kochupurakkal et al.,
2005). This would be consistent with the observation that
addition of exogenous EGFR ligands did not improve N-TERT
KC growth in the absence of TET (Supplementary Figure S1
online), suggesting that these cells produce sufficient levels of
AREG to sustain growth. Surprisingly, we found that even
high concentrations of recombinant EGFR ligands, up to 100
times the EGF concentration in regular KC growth media,
could not rescue KC growth in AREG knockdown cells
(Figure 5). These results cannot be explained by a lack of
activity of recombinant EGFR ligands because addition
of EGF to cultures treated with anti-AREG restored cell
growth to control levels and prevented the appearance
of differentiated cells (Figure 5). Moreover, addition
of ligands to AREG knockdown cells induced ERK phoshor-
ylation (Figure 3) and profoundly changed the cell morpho-
logy, with the appearance of large, multinucleated KCs
(Figure 5).
In support of AREG as the predominant KC EGFR ligand
mediating autocrine growth, our data show that AREG
knockdown induces KC differentiation (Figure 4). Interest-
ingly, it was previously reported that inhibition of EGFR
signaling in KCs leads to growth arrest, terminal differentia-
tion, and induction of keratins 1 and 10 (Poumay and
Pittelkow, 1995; Peus et al., 1997). Taken together, our data
further show that the endogenously expressed AREG TM-
precursor protein regulates KC growth and differentiation in a
way that cannot be substituted by soluble EGFR ligands,
including AREG itself. These data suggest that in addition to
mature and soluble AREG consisting of the EGF domain,
other regions of the AREG TM precursor (possibly the carboxy
(C)-terminal domain) have an important role in the regulation
of KC growth and differentiation. Interestingly, autocrine ERK
phosphorylation (Figure 3) and KC growth (Figure 4a) were
strongly blocked in the presence of the metalloproteinase
inhibitor GM6001 (Stoll et al., 2010), further supporting
published work (Sanderson et al., 2006) suggesting that
proteolytic cleavage of the AREG TM precursor is required for
proper function.
In support of an important function of the cytoplasmic
domain for cell growth and differentiation, we show that
expression of the AREG TM precursor in knockdown cells
markedly restores KC proliferation (Figure 6), strongly
reverses the morphological changes, and prevents the
expression of KC differentiation markers (Figures 4 and 6).
However, it should be noted that the rescue was not
complete. One possible explanation for this could be the
observed TET-induced downregulation of EGFR (Supplemen-
tary Figure S2 online). Alternatively, it might be plausible that
a Flag-Tag present at the C-terminus of our construct
interferes with its putative intracellular functions. Further
studies are required to test these possibilities.
Interestingly, it was previously shown that the C-terminal
fragment of HB-EGF translocates to the nucleus, where it
binds to and inactivates promyelocytic zinc finger protein, a
transcriptional inhibitor of cyclin A (Nanba et al., 2003).
Whether the C-terminal domain of AREG has a similar role
during cell-cycle progression is unknown. However, the
appearance of large, multinucleated cells in growth factor-
treated AREG knockdown cells (Figure 5) suggests that it
might be important for cytokinesis. Recently, Isokane et al.
(2008) showed that 12-O-tetradecanoylphorbol-13-acetate-
induced AREG shedding results in endocytosis of both
TM–cytoplasmic AREG fragments and unshed TM precursors
in HeLa cells. It was shown that the AREG precursor
translocates from the plasma membrane to the nucleus,
where it binds to lamin A, a nuclear envelope protein,
leading to heterochromatinization and transient suppression
of global gene transcription. Interestingly, another study
showed that mutations in lamin A delay the onset and
progression of cytokinesis, leading to premature aging in
dermal fibroblasts (Dechat et al., 2007). Further studies are
needed to determine the relative importance of AREG and
lamin A in controlling proliferation in skin KCs.
In summary, our data show that conditional, lentivirus-
mediated gene knockdown is a versatile tool for regulating
endogenous gene expression in non-transformed human KCs.
Using this tool, we show that autocrine human KC growth
and differentiation depend on endogenously expressed
AREG precursor protein, strongly suggesting a previously
unreported function for the MP-generated C-terminal domain
of the AREG TM precursor. Further elucidation and targeting
of this function might be of therapeutic potential in
inflammatory and neoplastic disorders of the skin and other
epithelial tissues.
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MATERIALS AND METHODS
Reagents
Recombinant human EGF was obtained from Peprotech (Rocky
Hill, NJ). Recombinant AREG, HB-EGF, and EPGN and Abs against
AREG, HB-EGF, and TGF-a were from R&D Systems (Minneapolis,
MN). The ErbB receptor tyrosine kinase inhibitor PD158780, the
MEK inhibitor U0126, the MP inhibitor GM6001, and puromycin
were purchased from Calbiochem (San Diego, CA). All other
chemicals were obtained from Sigma (St Louis, MO).
Cell culture
The immortalized, non-transformed human KC cell line N-TERT-2G
was provided by Dr James Rheinwald (Boston, MA), and was
routinely grown in KC serum-free medium (Invitrogen, Carlsbad,
CA) as previously described (Dickson et al., 2000). NHKs and
293FT human embryonic kidney cells were cultured as described
previously (Stoll et al., 2010).
Inducible and constitutive lentivirus-mediated RNA
interference and gene expression
Small hairpin RNAs (shRNAs) against AREG and EGFP were cloned
into pLenti4/Block-iT-DEST (Invitrogen). The complementary DNA
for EGFP was cloned into the TET-regulated lentiviral vector pLenti4/
TO/V5-DEST (Invitrogen) as previously described (Stoll et al., 2010).
Constructs encoding the AREG TM precursor with a C-terminal
Flag-Tag or AREG ECD with a 30 His-Tag (Figure 6a) were cloned
into the lentiviral expression vector pLVX-aAcGFP-N1 (Clontech,
Mountain View, CA) under the control of a constitutive cytomegalo-
virus promotor. Lentiviral particles were produced according to the
manufacturer’s instruction (Invitrogen or Clontech) and used to stably
transduce the TET repressor protein-expressing cell line N-TERT-TR
as described previously (Rittie´ et al., 2009; Stoll et al., 2010).
Autocrine cell culture conditions
N-TERT KCs were plated at 5% confluence in complete KC serum-free
medium (Invitrogen) and grown to 40–50% confluence. Cells were then
incubated in basal M154 medium (Cascade Biologics, Portland, OR)
or KC serum-free medium for 48hours with or without 1mgml1 TET.
Immunofluorescence
N-TERT-TR-EGFP cells were plated on glass coverslips and grown
and treated as indicated in the figure legends. The cells were fixed
with 4% paraformaldehyde, counterstained with 4’-6-diamidino-2-
phenylindole, and photographed.
RNA isolation and quantitative real-time PCR
Total RNA was isolated and reverse transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA). Real-time PCR analysis was performed using
TaqMan gene-expression assays from Applied Biosystems as
previously described (Rittie´ et al., 2009; Stoll et al., 2010). Target
gene expression was normalized to the control gene 36B4 (RPLP0;
Laborda, 1991; Minner and Poumay, 2009), and was expressed as %
of untreated controls or as percentage of the control gene 36B4.
Cell growth assays
N-TERT KCs were plated at 1% confluence in complete KC serum-
free medium (Invitrogen) and grown until the colonies contained
approximately four to eight cells as previously described for NHKs
(Pittelkow et al., 1993). Cells were then incubated under autocrine
culture conditions in basal KC serum-free medium for 6–8 days with
and without 1mgml1 TET. Blocking anti-EGFR ligand or isotype
control Abs, with or without various concentrations of AREG, EGF,
EPGN, HB-EGF, and TGF-a, were added to the cultures at the same
time as TET. To assess the KC cell growth, cells were washed with
phosphate-buffered saline, trypsinized, and counted using a hemo-
cytometer or stained with crystal violet and photographed.
Phospho-Erk western blotting
N-TERT-2G cells were grown in keratinocyte serum-free medium
medium to 40–50% confluence, followed by basal M154 medium
for 48 hours. Incubation with inhibitors and western blotting were
performed as previously described (Stoll et al., 2010).
ELISA
AREG protein levels in KC-conditioned medium were measured
using an AREG DuoSet ELISA (R&D Systems) as previously described
(Kansra et al., 2004; Stoll et al., 2010).
Statistical analysis
Data are expressed as mean±standard error of the mean (SEM).
Statistical analyses were performed using paired or independent two-
tailed Student’s t-tests.
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